INSIGHTS ON CELL & GENE MANUFACTURING AND LOGISTICS

• Control Software For Industrial Applications

  Learn how integrated process control, scalable workflows, and secure automation help teams plan, run, and analyze bioprocesses efficiently across research, development, and manufacturing.

• Materials Matter: Reframing Raw Material Strategy In Cell And Gene Therapy Development

  Scaling iPSC-based therapies from lab to CGMP manufacturing demands tightly controlled cryopreservation, risk-based QC, and strategic automation to preserve cell viability, consistency, and regulatory readiness.

• Cell And Gene Therapy CDMOs: On The Path To $75 Billion in Services?

  Cell and gene therapy (CGT) developers – and thus their service providers – have had their share of ups and downs. But what do the promise and uneven realities of these therapies add up to in the development and manufacturing outsourcing sector? According to a Towards Healthcare report, despite the bumps in the road, in 2025 the global CGT CDMO market grew to $8.2 billion. What of future predictions? Here's a detailed analysis.

• The Stepwise Path Lilly Mapped From Paper To Digital Logbooks

  Eli Lilly and Company started at the front lines, on the shop floor gathering operator input, when switching from paper to digital logbooks.

• How Connected Manufacturing Operations And AI Optimize Production

  While 53% of manufacturers are digital, a lack of system connectivity stalls AI progress. Learn how to break down data silos to reduce rework, accelerate quality reviews, and ensure AI readiness.

• The European CDMO Model, Powering Biologics Innovation

  Europe’s integrated CDMO model is reshaping biologics development by aligning early science, manufacturing, and quality to accelerate scalable, compliant therapies from concept to clinic.

• Simplifying Cell Harvest with Single-Use Centrifuge Bags

  Optimize small-scale cell harvest with sterile, single-use bioprocess bags. High-performance film and a closed-system design ensure process integrity while reducing contamination risks.

• Validate Cryopreservation As A Defined Input, Not A Variable

  Treating cryopreservation as a validated, controlled input improves consistency, quality, and patient outcomes by reducing variability across cell therapy manufacturing, storage, and distribution.

• Accelerate Your Trials With An End‑To‑End Supply Chain Model

  An end-to-end supply chain model helps clinical trials move faster while maintaining visibility, control, and risk management across complex, temperature‑sensitive, and global operations.

• Where Innovation Is Moving The Advanced Therapies Supply Chain

  Assimilate how advanced therapy supply chains are evolving toward patient-centric, risk-managed, digitally connected models to support scale, reliability, and regulatory confidence globally today.